349 related articles for article (PubMed ID: 30041763)
21. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
22. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
[TBL] [Abstract][Full Text] [Related]
23. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
[TBL] [Abstract][Full Text] [Related]
24. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
Deguchi H; Yamazaki H; Kamitani T; Yamamoto Y; Fukuhara S
Adv Ther; 2021 Jul; 38(7):3937-3947. PubMed ID: 34091865
[TBL] [Abstract][Full Text] [Related]
25. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
[TBL] [Abstract][Full Text] [Related]
30. Vonoprazan: A Review in Helicobacter pylori Infection.
Shirley M
Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
[TBL] [Abstract][Full Text] [Related]
31. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
33. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
[TBL] [Abstract][Full Text] [Related]
34. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Kusano C; Gotoda T; Suzuki S; Ikehara H; Moriyama M
J Gastroenterol; 2018 Jun; 53(6):718-724. PubMed ID: 29110085
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
36. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
Horie R; Handa O; Ando T; Ose T; Murakami T; Suzuki N; Sendo R; Imamoto E; Itoh Y
Helicobacter; 2020 Aug; 25(4):e12698. PubMed ID: 32368846
[TBL] [Abstract][Full Text] [Related]
38. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
Eto H; Suzuki S; Kusano C; Ikehara H; Ichijima R; Ito H; Kawabe K; Kawamura M; Yoda Y; Nakahara M; Gotoda T
Helicobacter; 2021 Apr; 26(2):e12788. PubMed ID: 33580612
[TBL] [Abstract][Full Text] [Related]
39. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
[TBL] [Abstract][Full Text] [Related]
40. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
